{"success":true,"data":{"pressRelease":{"id":"18995","rtpr_id":"nGNXc48BmH","ticker":"BCAX","exchange":"NASDAQ","all_tickers":["BCAX"],"title":"Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET","author":"Globe Newswire","published_at":"2026-05-04T12:30:00.519Z","article_body":"BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq:\nBCAX), a clinical-stage biopharmaceutical company committed to bringing\ntransformative bifunctional therapies to patients with solid tumors, today\nannounced that it will report first quarter 2026 financial results and\nbusiness updates before the market opens on Monday, May 11, 2026. Bicara will\nhost a conference call to discuss the financial results and business updates\nat 8:30 a.m. ET the same day. Individuals may register for the conference call\nby clicking the link here\n(https://www.globenewswire.com/Tracker?data=VVOs7k6d31N-Iy93ISQlgWMRrHBCWJYSABhH3rNt5tjjDT30DGdsdb-sgz9DqLvgl9XQVKg3hPkld6_cLKyLgUw5BW6LEJejbhd7AoDDKRA-vHE6M-SABa9BAE0CUM3L39qai__jHoTaLPB4APlwgP7v2aD26tN_kY7lQNwVpbU=).\nOnce registered, participants will receive dial-in details and a unique PIN\nthat will allow them to access the call. To access the live webcast, please\nvisit the “Events & Presentations\n(https://www.globenewswire.com/Tracker?data=L3PVVBbpNWepqW_R3Sk2gEdZTM52DS-6N7fG6q1dHj43fN04wPzB_Fc5w54ikKiWwsxDtUfLDlcMHIF_L4iwjl2OsHHo7ONuDCVeuSKJlN9dRQYgQJwLhlDhWG88Xya9MLWLPHzF-I-P2SqXAUOc2w==)”\nsection within the Investors page on the Bicara website. A replay of the\nwebcast will be available for 30 days following the event.\n\nAbout Bicara Therapeutics\n\nBicara is a clinical-stage biopharmaceutical company committed to bringing\ntransformative bifunctional therapies to patients with solid tumors. Bicara\nhas built a platform designed to facilitate the development of bifunctional\ntherapies that precisely target the tumor and deliver a tumor-modulating\npayload to the tumor site. This approach was deployed in the development of\nBicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional\nepidermal growth factor receptor (EGFR) directed monoclonal antibody bound to\na human transforming growth factor beta (TGF-β) ligand trap. By combining\nthese two clinically validated targets, ficerafusp alfa has the potential to\nexert potent anti-tumor activity by simultaneously blocking both cancer\ncell-intrinsic EGFR survival and proliferation, as well as the\nimmunosuppressive TGF-β signaling within the tumor microenvironment (TME).\nFicerafusp alfa directs the TGF-β inhibitor into the immediate TME through\nthe binding of EGFR on tumor cells, which Bicara believes will lead to deep\nand durable responses and an increase in overall survival, while reducing the\npotential adverse effects previously associated with systemic TGF-β\ninhibition. Ficerafusp alfa is being developed in head and neck squamous cell\ncarcinoma, where there remains a significant unmet need, as well as other\nsolid tumor types. For more information, please visit www.bicara.com or\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=kQ-ZHHgSJxHxlqCpV2qxvVDcs6rlB_o3pFHNZsprv2ZQdeiaj2xo_Nb56UEPZJftu7GfrRCGx8uYYfe1Xg72PqQRT72iBT4tQdLxk7MM508jui2sP7eMPGNgn-yTiCdt)\nand X\n(https://www.globenewswire.com/Tracker?data=NoGwljB1K_wRgYDZUSp5uyeZGJzfLLXoQwIb4Z1Nz29Ec7-iIaaV9b0JoWM6y8a2ZHjh09P0JuM-meMxaF112w==).\n\nContacts:\n\nInvestors \nRachel Frank \nIR@bicara.com\n\nMedia \nTim Palmer\ntim.palmer@bicara.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXc48BmH","title":"Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET","author":"Globe Newswire","ticker":"BCAX","created":"2026-05-04T12:30:00.519Z","tickers":["BCAX"],"exchange":"NASDAQ","article_body":"BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq:\nBCAX), a clinical-stage biopharmaceutical company committed to bringing\ntransformative bifunctional therapies to patients with solid tumors, today\nannounced that it will report first quarter 2026 financial results and\nbusiness updates before the market opens on Monday, May 11, 2026. Bicara will\nhost a conference call to discuss the financial results and business updates\nat 8:30 a.m. ET the same day. Individuals may register for the conference call\nby clicking the link here\n(https://www.globenewswire.com/Tracker?data=VVOs7k6d31N-Iy93ISQlgWMRrHBCWJYSABhH3rNt5tjjDT30DGdsdb-sgz9DqLvgl9XQVKg3hPkld6_cLKyLgUw5BW6LEJejbhd7AoDDKRA-vHE6M-SABa9BAE0CUM3L39qai__jHoTaLPB4APlwgP7v2aD26tN_kY7lQNwVpbU=).\nOnce registered, participants will receive dial-in details and a unique PIN\nthat will allow them to access the call. To access the live webcast, please\nvisit the “Events & Presentations\n(https://www.globenewswire.com/Tracker?data=L3PVVBbpNWepqW_R3Sk2gEdZTM52DS-6N7fG6q1dHj43fN04wPzB_Fc5w54ikKiWwsxDtUfLDlcMHIF_L4iwjl2OsHHo7ONuDCVeuSKJlN9dRQYgQJwLhlDhWG88Xya9MLWLPHzF-I-P2SqXAUOc2w==)”\nsection within the Investors page on the Bicara website. A replay of the\nwebcast will be available for 30 days following the event.\n\nAbout Bicara Therapeutics\n\nBicara is a clinical-stage biopharmaceutical company committed to bringing\ntransformative bifunctional therapies to patients with solid tumors. Bicara\nhas built a platform designed to facilitate the development of bifunctional\ntherapies that precisely target the tumor and deliver a tumor-modulating\npayload to the tumor site. This approach was deployed in the development of\nBicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional\nepidermal growth factor receptor (EGFR) directed monoclonal antibody bound to\na human transforming growth factor beta (TGF-β) ligand trap. By combining\nthese two clinically validated targets, ficerafusp alfa has the potential to\nexert potent anti-tumor activity by simultaneously blocking both cancer\ncell-intrinsic EGFR survival and proliferation, as well as the\nimmunosuppressive TGF-β signaling within the tumor microenvironment (TME).\nFicerafusp alfa directs the TGF-β inhibitor into the immediate TME through\nthe binding of EGFR on tumor cells, which Bicara believes will lead to deep\nand durable responses and an increase in overall survival, while reducing the\npotential adverse effects previously associated with systemic TGF-β\ninhibition. Ficerafusp alfa is being developed in head and neck squamous cell\ncarcinoma, where there remains a significant unmet need, as well as other\nsolid tumor types. For more information, please visit www.bicara.com or\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=kQ-ZHHgSJxHxlqCpV2qxvVDcs6rlB_o3pFHNZsprv2ZQdeiaj2xo_Nb56UEPZJftu7GfrRCGx8uYYfe1Xg72PqQRT72iBT4tQdLxk7MM508jui2sP7eMPGNgn-yTiCdt)\nand X\n(https://www.globenewswire.com/Tracker?data=NoGwljB1K_wRgYDZUSp5uyeZGJzfLLXoQwIb4Z1Nz29Ec7-iIaaV9b0JoWM6y8a2ZHjh09P0JuM-meMxaF112w==).\n\nContacts:\n\nInvestors \nRachel Frank \nIR@bicara.com\n\nMedia \nTim Palmer\ntim.palmer@bicara.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-04T12:30:00.578354142Z","server_sent_at_ms":1777897800578},"received_at":"2026-05-04T12:30:00.636Z","source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286695/0/en/bicara-therapeutics-to-report-first-quarter-2026-financial-results-and-business-updates-on-may-11-2026-at-8-30-am-et.html"},"analysis":{"id":"13793","press_release_id":"18995","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Bicara Therapeutics announced it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026.\n\nThe company will host a conference call to discuss these results at 8:30 a.m. ET on the same day.\n\nEvent details and registration links are provided for investors to access the live webcast or dial-in.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Earnings call announcement -- no action."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Rachel Frank","role":"Investor Contact"},{"name":"Tim Palmer","role":"Media Contact"}],"products":["ficerafusp alfa","BCA101"],"companies":[{"name":"Bicara Therapeutics Inc.","ticker":"BCAX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of an upcoming earnings conference call. No financial results or material business updates are disclosed in the release itself."},"tickerRelevance":{"others":[],"primary":"BCAX"},"globalImportance":5,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings-announcement","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bicara Therapeutics announced it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026.\n\nThe company will host a conference call to discuss these results at 8:30 a.m. ET on the same day.\n\nEvent details and registration links are provided for investors to access the live webcast or dial-in.","key_figures":{},"named_entities":{"people":[{"name":"Rachel Frank","role":"Investor Contact"},{"name":"Tim Palmer","role":"Media Contact"}],"products":["ficerafusp alfa","BCA101"],"companies":[{"name":"Bicara Therapeutics Inc.","ticker":"BCAX"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T15:40:32.868Z","global_importance":5,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings-announcement","sectorWeight":"biotech"}},"durationMs":86482,"modelName":"glm-4.7"}}